OMS,
1 de septiembre de 2015
Contenidos
Regulatory
Matters
Abiraterone
acetate
............................................................................
5
Adefovir
pivoxil
....................................................................................5
Anagliptin
............................................................................................
5
Asunaprevir
and daclatasvir hydrochloride
..........................................5
Crizotinib
...........................................................................................
..6
Denosumab
.........................................................................................
6
Dimethyl
fumarate................................................................................6
Ethinylestradiol
/etonogestrel vaginal ring ..........................................
7
Ferumoxytol
........................................................................................
7
Fusidic
acid and HMG-CoA reductase inhibitors
.................................. 7
Ibuprofen
.............................................................................................
8
Indapamide
...........................................................................................
8
Influenza
HA vaccine
..........................................................................
..8
Interferon
beta-1a
................................................................................
9
Ivabradine
.............................................................................................
9
Methotrexate
.......................................................................................
10
Methylphenidate
transdermal system .................................................
10
Methylprednisolone
(intravenous injection) ......................................... 10
Non-aspirin
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) ............ 11
Pregabalin
.............................................................................................11
Sorafenib
..............................................................................................
12
Technetium
(99mTc) hydroxymethylenediphosphonate injection ......... 12
Tramadol
hydrochloride
.....................................................................
...12
Ustekinumab
..........................................................................................13
Ziprasidone
............................................................................................13
Safety
of medicines
Codeine
Cough-and-Cold Medicines in Children .............................15
Combined
hormonal birth control products
....................................15
Denosumab
.....................................................................................
15
Diazoxide
........................................................................................
16
Febuxostat
......................................................................................
16
Ibuprofen
in high dose (≥2400mg/day)..........................................
16
Influenza
vaccine
.............................................................................
17
Latanoprost
eye drop
......................................................................
17
Melatonin
.........................................................................................
18
Sodium
glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin,
dapagliflozin,
empagliflozin) ..... 18
Zoledronic
acid infusion
.....................................................................
18
Signal
Atomoxetine
and Dystonia in paediatric patients
.................................. 20
Vemurafenib
and Tumour lysis syndrome
............................................ 25
Feature
Summary
of Recommendations from the Twelfth Meeting of the WHO
Advisory
Committee on Safety of Medicinal Products (ACSoMP) .............. 30
Implementing
Patient Reporting of Adverse Reactions in Ghana ............. 32
disponible
en http://bit.ly/1KphTCr
